Salix Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 9 Calls Today's Calls

Call Details Salix Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009) Mon, Nov 9, 2009, 5:00 pm Eastern Listen to the archived event audio About Salix Pharmaceuticals, Inc. (NasdaqGS:SLXP) Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States. Its products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. The company also offers Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; Apriso, for the maintenance of remission of ulcerative colitis in adults; and Colazal capsules for the treatment of ulcerative colitis. Salix Pharmaceuticals’ products under development include Balsalazide Disodium tablets for ulcerative colitis; Crofelemer for HIV-associated diarrhea; Vapreotide acetate for acute esophageal variceal bleeding; and Metoclopramide-Zydis for the treatment of gastroesphageal reflux and gastroparesis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; ALW Partnership; Debiopharm Group; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings